A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200%

Dec 19 2022 by Business Insider

 
Madrigal Pharmaceuticals is hoping to succeed where others have failed in treating NASH, a serious liver disease.

Pramote Polyamate/Getty Images

Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NASH. As a result, its stock has increased by more than 200%. NASH is a serious liver condition that does not have an FDA-approved treatment.

Madrigal Pharmaceuticals' stock jumped more than 200% on Monday after the biotech released positive results for its...

Continue Reading A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200%